Enliven Therapeutics, Inc. · NASDAQ:ELVN

Hohl Benjamin sold 6,018 Enliven Therapeutics, Inc. shares (Form 4)

Traded Oct 19, 2026 · Filed Oct 21, 2026

On Oct 19, 2026, Hohl Benjamin (CHIEF FINANCIAL OFFICER) sold 6,018 Enliven Therapeutics, Inc. shares at US$38.48 for US$232K under a trading plan, leaving 38,000 shares. Filed Oct 21, 2026 (Form 4).

Sold
6,018 shares
Price
US$38.48
Value
US$232K
Holding after
38,000 shares
Trading plan
Yes (Made under a plan set in advance)
Role
CHIEF FINANCIAL OFFICER

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Oct 19, 2026Common StockOption exercise6,018US$14.8544,018Direct
Oct 19, 2026Common StockSale6,018US$38.4838,000Direct

Source

Download original · View original at SEC

Related